Flu News Day, 7/27/2022

Read the latest on influenza vaccines and upcoming funding opportunities in this week’s roundup.

July 2022

Message in a bottle: mRNA vaccination for influenza

Compared to current seasonal influenza vaccines, mRNA influenza vaccines could increase global equity, more effectively address influenza threats and better prepare global infrastructure for a future universal influenza vaccine. While current influenza vaccines require at least six months to prepare, mRNA vaccines could be developed in a matter of weeks. As such, mRNA vaccines can rapidly respond to antigenic shifts, better preparing the world for regional nuances and pandemic threats. Additionally, mRNA vaccines are relatively cheap, safe, easily transportable and many LMICs are expanding their mRNA capacity through WHO Technology Transfer Hubs. Currently, 95% of influenza vaccines are distributed to only 50% of the global population; mRNA platforms could potentially enable vaccines to reach regions of the world currently unprotected from influenza. Learn more about the benefits and challenges of implementing mRNA influenza vaccines here.

Read the full article here
July 2022

India-based Gennova Biopharmaceuticals’ mRNA vaccine gets DCGI nod

The first mRNA COVID-19 vaccine developed in India has officially been approved for emergency use by the Drug Controller General of India. Developed by Gennova Biopharmaceuticals, the two-dose intramuscular vaccine is notably stable at 2-8°C, a storage temperature many degrees above that of the mRNA vaccines currently available. Because of this, the Gennova COVID-19 vaccine can be distributed through pre-existing cold-chain infrastructure in India. Gennova Biopharmaceuticals officials estimate that a third of India’s population could benefit from this vaccine and there is an even greater global demand for this type of thermostable vaccine. Learn more here.

Read the full article here
June 2022

Flagship unwraps new AI biotech that looks to predict variants before they’re here

Rather than waiting idly for new mutations of SARS-CoV-2 to circulate, new AI may allow researchers to develop vaccines before novel variants emerge. Apriori Bio, a biotech founded in 2020 to address “ultra-dynamic” threats such as HIV and influenza, works with public and private partners to create databases of millions of synthetic variants. Researchers test these synthetically predicted variants to learn how well they bind to therapeutic and post-infection antibodies. Scientists can then design vaccines and antibodies that bind to the variants that current vaccines may fail to address. Read more about this pro-active approach to variant threats here.

Read the full article here
July 2022

Reactogenicity and Concomitant Administration of the COVID-19 Booster and Influenza Vaccine

As experts consider co-administering seasonal influenza and COVID-19 booster vaccines, new research suggests that simultaneous vaccination only slightly increases reactogenicity, expected signs and symptoms post-vaccination, typically as a result of the immune response. Using data from CDC’s v-safe, a voluntary self-reporting platform, researchers found only an 8% increase in reactogenicity for those vaccinated with Pfizer’s COVID-19 booster and the 2021-22 seasonal influenza vaccine (compared to those only vaccinated with the Pfizer vaccine) and an 11% increase for those vaccinated with Moderna’s COVID-19 booster and influenza (compared to those only vaccinated with the Moderna vaccine). Reported symptoms typically included headaches, muscle pain, and fatigue, and severe adverse effects from receiving both vaccinations were infrequent. Moreover, those who received a Pfizer and seasonal influenza vaccine did not experience absenteeism from school, work, or other normal activities any more than those who only received Pfizer’s COVID-19 vaccine. Simultaneously administering seasonal influenza and COVID-19 booster vaccines could dramatically increase uptake of both vaccines. These findings should encourage health systems to design processes for co-administration and can inform communication campaigns that endorse this strategy; read more here.

Read the full article here

Funding Opportunities & Announcements

Centre for Doctoral Training: environmental solutions to zoonoses [Grant]
NERC, BBSRC, MRC / June 23, 2022 /July 29, 2022             Apply Here

Planning Grant for Global Infectious Disease Research Training Program [Discretionary Grant]                                                                                                         NIH /January 8, 2021 / October 28, 2022                                  Apply Here

NIAID Resource-Related Research Projects [Discretionary Grant]
NIAID / November 22, 2019 / January 7, 2023                       Apply Here

Data Management Coordinating Center for Diagnostic Centers of Excellence [Cooperative Agreement]                                                                        NIH / July 10, 2022 / August 10, 2022                                       Apply Here

Limited Competition: Research Resource for Human Organs and Tissues [Cooperative Agreement]                                                                                             NIH/ December 25, 2021 / September 25, 2022                     Apply Here

USAID/Uganda Health Activity [Discretionary Grant]                               Uganda USAID-Kampala / July 18, 2022 / August 22, 2022 Apply Here

Public Health Intervention Development [Grant]
Medical Research Council / July 15, 2022 / September 15, 2022 Apply Here

Pediatric Disaster Care [Discretionary Grant]                                       Department of Health and Human Services / July 26, 2022 / August 26, 2022                                                                                                                   Apply Here

Emerging Infectious Disease and Preparedness Grant [Grant]                SAEMF / June 29, 2022 / August 1, 2022                                   Apply Here